Pharmacokinetics and Metabolism of Naringin and Active Metabolite Naringenin in Rats, Dogs, Humans, and the Differences Between Species.
dog
human
metabolism
naringenin
naringin
pharmacokinetics
rat
species differences
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2020
2020
Historique:
received:
17
11
2019
accepted:
10
03
2020
entrez:
16
4
2020
pubmed:
16
4
2020
medline:
16
4
2020
Statut:
epublish
Résumé
Pharmacokinetics provides a scientific basis for drug product design, dosage regimen planning, understanding the body's action on the drug, and relating the time course of the drug in the body to its pharmacodynamics and/or toxic effects. Recently, naringin, a natural flavonoid, was approved for clinical trials as a first-class new drug product by the China Food and Drug Administration, owing to its nonclinical efficacy in relieving cough, reducing sputum, and low toxicity. Previous reports focused on the pharmacokinetic studies of naringin or its active metabolite naringenin in rats, which were scattered and insufficient because naringin was coadministered with mixtures such as herbs, fruits, and other traditional medicines. The purpose of this study was to evaluate the pharmacokinetics and metabolism of naringin and naringenin, following oral and intravenous administration of naringin in rats, dogs, and humans, which can be beneficial for new drug development. Separate bioanalytical methods were developed and validated to determine the concentrations of naringin and its active metabolite naringenin in biological samples obtained from rats, dogs, and humans. Comprehensive nonclinical and clinical data were used to estimate the pharmacokinetic parameters of naringin and naringenin. Experiments included single-dose studies (oral and intravenous administration), multiple-dose studies, and an assessment of food-effects. Furthermore, the metabolism of naringin and naringenin was studied in rat and human liver and kidney microsomes. All biological samples were analyzed using liquid chromatography-tandem mass spectrometry. The pharmacokinetic parameters of naringin and naringenin were calculated and the results show an insignificant influence of high-fat diet and insignificant accumulation of the drugs after multiple dosing. Twelve metabolites were detected in the liver and kidney microsomes of rats and humans; naringin metabolism was a complex process simultaneously catalyzed by multiple human enzymes. All evaluated species demonstrated differences in the pharmacokinetics and metabolism of naringin and naringenin. The results can be used to design a dosage regimen, deepen understanding of mechanisms, and accelerate new drug development. http://www.chinadrugtrials.org.cn/eap/main, identifiers CTR20130704 and CTR20190127.
Sections du résumé
BACKGROUND
BACKGROUND
Pharmacokinetics provides a scientific basis for drug product design, dosage regimen planning, understanding the body's action on the drug, and relating the time course of the drug in the body to its pharmacodynamics and/or toxic effects. Recently, naringin, a natural flavonoid, was approved for clinical trials as a first-class new drug product by the China Food and Drug Administration, owing to its nonclinical efficacy in relieving cough, reducing sputum, and low toxicity. Previous reports focused on the pharmacokinetic studies of naringin or its active metabolite naringenin in rats, which were scattered and insufficient because naringin was coadministered with mixtures such as herbs, fruits, and other traditional medicines. The purpose of this study was to evaluate the pharmacokinetics and metabolism of naringin and naringenin, following oral and intravenous administration of naringin in rats, dogs, and humans, which can be beneficial for new drug development.
METHODS
METHODS
Separate bioanalytical methods were developed and validated to determine the concentrations of naringin and its active metabolite naringenin in biological samples obtained from rats, dogs, and humans. Comprehensive nonclinical and clinical data were used to estimate the pharmacokinetic parameters of naringin and naringenin. Experiments included single-dose studies (oral and intravenous administration), multiple-dose studies, and an assessment of food-effects. Furthermore, the metabolism of naringin and naringenin was studied in rat and human liver and kidney microsomes. All biological samples were analyzed using liquid chromatography-tandem mass spectrometry.
RESULTS
RESULTS
The pharmacokinetic parameters of naringin and naringenin were calculated and the results show an insignificant influence of high-fat diet and insignificant accumulation of the drugs after multiple dosing. Twelve metabolites were detected in the liver and kidney microsomes of rats and humans; naringin metabolism was a complex process simultaneously catalyzed by multiple human enzymes. All evaluated species demonstrated differences in the pharmacokinetics and metabolism of naringin and naringenin.
CONCLUSION
CONCLUSIONS
The results can be used to design a dosage regimen, deepen understanding of mechanisms, and accelerate new drug development.
CLINICAL TRIAL REGISTRATION
BACKGROUND
http://www.chinadrugtrials.org.cn/eap/main, identifiers CTR20130704 and CTR20190127.
Identifiants
pubmed: 32292344
doi: 10.3389/fphar.2020.00364
pmc: PMC7118210
doi:
Types de publication
Journal Article
Langues
eng
Pagination
364Informations de copyright
Copyright © 2020 Bai, Peng, Yang, Zou, Liu, Wu, Fan, Li, Zeng and Su.
Références
J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Sep 1;1000:112-9
pubmed: 26222904
J Agric Food Chem. 2012 Dec 26;60(51):12435-42
pubmed: 23210543
Int J Pharm. 2006 Jan 13;307(2):292-9
pubmed: 16289985
Planta Med. 2011 Jan;77(1):16-21
pubmed: 20645246
J Chromatogr Sci. 2018 Aug 1;56(7):611-618
pubmed: 29701749
Int Immunopharmacol. 2012 Jul;13(3):301-7
pubmed: 22575871
Int Immunopharmacol. 2011 Oct;11(10):1606-12
pubmed: 21640201
Pulm Pharmacol Ther. 2015 Aug;33:59-65
pubmed: 26169899
Biopharm Drug Dispos. 2012 Apr;33(3):123-34
pubmed: 22374702
J Med Food. 2012 Oct;15(10):894-900
pubmed: 22985397
Eur J Pharmacol. 2012 Sep 5;690(1-3):207-13
pubmed: 22766066
J Pharm Biomed Anal. 2012 Jan 25;58:58-64
pubmed: 22018980
J Pharm Biomed Anal. 2012 Jul;66:271-7
pubmed: 22521636
Food Funct. 2011 Jan;2(1):11-7
pubmed: 21773581
J Pharm Biomed Anal. 2004 Jan 27;34(1):159-66
pubmed: 14738930
Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):413-24
pubmed: 18524030
J Chromatogr Sci. 2014 Aug;52(7):654-60
pubmed: 23839803
Inflamm Res. 2013 Dec;62(12):1053-61
pubmed: 24085318
Metabolites. 2013 Sep 30;3(4):867-80
pubmed: 24958255
J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Jul 1;993-994:75-80
pubmed: 26000860
Environ Toxicol Pharmacol. 2011 May;31(3):485-9
pubmed: 21787720
Mol Med Rep. 2012 Dec;6(6):1343-50
pubmed: 22965302
Eur J Drug Metab Pharmacokinet. 2017 Aug;42(4):647-656
pubmed: 27744636
Environ Toxicol Pharmacol. 2014 Jul;38(1):279-87
pubmed: 24998504
J Pharm Biomed Anal. 2018 Nov 30;161:262-272
pubmed: 30172881
Food Chem Toxicol. 2013 Oct;60:1-9
pubmed: 23871784
Food Chem Toxicol. 2014 Apr;66:65-75
pubmed: 24462649
Int J Mol Sci. 2018 Jan 23;19(2):
pubmed: 29360768
Front Pharmacol. 2019 Jan 28;10:34
pubmed: 30761003
J Agric Food Chem. 2000 Jan;48(1):56-9
pubmed: 10637051
Food Chem Toxicol. 2013 Aug;58:133-40
pubmed: 23603004